Effect of Eleng Capsule on Endometrial Antibody in Patients with Endometriosis
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
This study found that Eleng Capsule and danazol similarly reduced endometrial antibody levels in endometriosis patients, and higher disease severity did not correlate with increased antibody levels.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
To assess the significance of endometrial antibody(EmAb)for the diagnosis and treatment of endometriosis(EMT),and the influence of Eleng Capsule(EC)on EMT,97 cases of EMT confirmed by pathological examination and laparoscopy were randomly allocated to 2 groups:EC group (65 cases,treated by EC 6 tid for 6 months)and control group (32 cases,treated by danazol 0.2 bid for 6 months).Serum EmAb content was detected by enzyme linked immunosorbent assay method.The severity of the disease was classified into three grades(mild,moderate and severe).The results showed that the positive rate of EmAb in the mild,moderate and severe cases was 66.67% , 76.19% and 57.45%, and the rate of EmAb turning to negative was 85.71% , 41.67% and 50.00% respectively.The rate of EmAb turning to negative was 51.85% and 56.25% in EC group and control group respectively (P 0.05 ).It is suggested that the positive rate of EmAb does not elevate with the severity of EMT.EmAb is more significant for the complementary diagnosis of mild cases and can turn negative easily after treatment.It is probably related to the transmission of EmAb to pelvic cavity and abdominal cavity in severe cases and the serum immune response being easily inhibited in mild cases.EC exerts a strong immunoregulatory effect and inhibit the level of serum EmAb.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (1)
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK